Livzon Pharmaceutical's (HKG:1513, SHE:000513) unit Livzon MABPharm received approval from China's National Medical Products Administration for Recombinant Human Follitropin Alfa Solution for Injection, according to a Monday Hong Kong bourse filing.
The product is indicated for anovulation, including polycystic ovary syndrome, ovarian stimulation in assisted reproductive technology procedures, and certain patients with severe luteinizing hormone and follicle-stimulating hormone deficiencies.
The drug is administered through a pre-filled injection pen and was developed as a biosimilar.